Background and objective Increased left ventricular mass (LVM), low ventricular ejection fraction (EF), and high pulse-wave velocity (PWV) relate to overall and cardiovascular mortality in patients with ESRD. The aim of this study was to determine the effect of online hemodiafiltration (HDF) versus low-flux hemodialysis (HD) on LVM, EF, and PWV.
Introduction
Cardiovascular disease is a considerable cause of morbidity and mortality in patients with ESRD (1) . The origin of cardiovascular disease is multifactorial; factors such as retention of uremic toxins, microinflammation, atherosclerosis, a fluctuating extracellular fluid volume, and hypertension have been implicated (2) (3) (4) .
Important alternative markers of cardiovascular risk are left ventricular mass (LVM), ejection fraction (EF), and pulse-wave velocity (PWV), the latter as a measure of arterial stiffness. LVM, EF, and PWV have all been repeatedly demonstrated to be relevant predictors of cardiovascular morbidity and mortality in patients with ESRD (5) (6) (7) (8) (9) . Regression of LVM has also been shown to be associated with a more favorable outcome in this population (10) . Studies on the natural course of LVM in patients with ESRD have reported stabilization or decrease of these measures over time (9, 11) , while the natural course of EF is to decrease slowly over time in this population (7, 12) .
Hemodiafiltration (HDF) is a dialysis modality that uses a combination of convective transport and diffusion to clear more and larger solutes compared with those cleared with conventional hemodialysis (HD) (13) . HDF reduces inflammatory measures related to atherosclerosis and improves intradialytic hemodynamic stability (14) , possibly advantageous factors in decreasing the risk of cardiovascular disease. Extended or frequent HD has been established to have a beneficial effect on cardiac morphology and function (15) . Thus, the question arises as to whether HDF may also have such an effect.
The aim of this study was to determine the effect of online HDF versus low-flux HD on the rate of change in LVM, EF, and PWV over time in a large population of patients with ESRD.
Materials and Methods

Patients
The present study included a subset of patients participating in the CONvective TRAnsport STudy (CONTRAST). Patients were recruited between June 2004 and December 2009. CONTRAST has been designed to investigate the effects of increased convective transport by online postdilution HDF compared with lowflux HD on all-cause mortality and cardiovascular morbidity and mortality (International Clinical Trials Registrations Platform: ISRCTN38365125) (13, 16) . This subset of the population consisted of patients who were treated in a medical center, where additional echocardiography measurements and PWV measurements were logistically possible. Patients in these centers who had given informed consent to participate in CONTRAST were requested to undergo echocardiography and PWV measurements.
CONTRAST was conducted in accordance with the Declaration of Helsinki and was approved by the medical ethics review boards of all participating dialysis centers. All patients provided informed consent before enrollment.
All patients were randomly assigned centrally by a computer-based randomization service (Julius Center University Medical Center, Utrecht, The Netherlands) in a 1:1 ratio for treatment with online HDF or continuation of lowflux HD, stratified by participating center (permuted blocks). Because of the nature of the intervention, patients, local study nurses, and investigators could not be blinded to treatment assignment.
Dialysis Procedures
Dialysis procedures have elaborately been described elsewhere (13, 16) . Routine patient care was performed according to the guidelines of the Quality of Care Committee of the Dutch Federation of Nephrology.
Data Collection
At baseline, standardized forms were used to collect demographic, clinical, and laboratory data; type of vascular access; duration of dialysis (dialysis vintage); and medical history. The data collection in CONTRAST has been described in detail previously (13, 16) .
In patients in the HDF group, infusion volumes (liters per treatment) were reported as the mean value of three consecutive treatment sessions preceding the quarterly visit. Convection volumes (liters per treatment) were calculated as the sum of the intradialytic weight loss and the substitution volume per session. The mean delivered convection volume during the trial was estimated as follows: mean delivered convection volume=(HDF treatments/total number of treatments)3mean convection volume of the three treatments preceding the quarterly visit.
Standard laboratory samples were analyzed in the local laboratories of the participating hospitals by standard laboratory techniques.
Echocardiography and PWV Measurements
Participants in 18 centers (n=342) were requested to undergo echocardiography at baseline, 6 months, 12 months, and annually thereafter.
Transthoracic two-dimensional echocardiography studies were performed on a midweek nondialysis day by an echocardiographer at the participating local hospital. The ultrasound investigations were assessed centrally by an independent experienced echocardiographer at the core laboratory (Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands), who was blinded to all other patient data, including treatment assignment. LVM was calculated using the formula of Devereux and Reickek (17) , modified in accordance with the recommendations of the American Society of Echocardiography (18). EF was computed automatically by the echocardiography software.
Participants in eight centers (n=189) were requested to undergo aortic PWV measurements in addition to the standard CONTRAST data collection at baseline and annually thereafter, on a midweek nondialysis day. The SphygomoCor system (PWV system and BP analysis system; PWV, Inc., Sydney, NSW, Australia) was used to assess PWV and analyze the arterial pulse contours. The method has a high reproducibility and is described in detail elsewhere (19) (20) (21) .
Statistical Analyses
Data were reported as means with SDs, medians with ranges, or proportions when appropriate.
Comparisons between treatment modality groups were analyzed with an unpaired t test for normally distributed variables, Mann-Whitney test for variables not normally distributed, and chi-squared test for binomial variables.
Linear mixed-effect models with a random intercept and slope were used to model changes over time in PWV, EF, and LVM. The means of LVM, EF, and PWV were compared between treatment groups, along with the rates of change. To explore whether rates of change differed depending on follow-up time, we calculated rates of change from baseline to 12 months and from baseline to end of follow-up of measurements. To elucidate, data from 1-year follow-up included the slopes of patients followed from baseline to 1 year. Data from 3 years of follow-up included the slopes of patients followed from baseline to 3 years.
Additional linear mixed models were performed by adding interaction terms for age, sex, residual kidney function, dialysis vintage, presence of diabetes, and presence of cardiovascular disease. Age and dialysis vintage were both tested as continuous variables and stratified below or above the median for the patient group under study. For patients in the HDF group, additional linear mixed-effect models were performed by adding interaction terms for mean convection volume. The latter was tested as a continuous variable, stratified above and below the median and in tertiles. All models were performed with adjustment for baseline LVM, EF, or PWV.
Results were considered statistically significant with P,0.05 (two-sided). All calculations were made by use of a standard statistical package (SPSS for Windows, version 20.0.1; SPSS, Inc., Chicago, IL).
Results
The baseline characteristics of the patients in whom LVM/EF and PWV were measured are depicted in Table 1 . No differences in patient characteristics were observed between treatment groups, nor in the echocardiography or in the PWV cohort. A total of 342 CONTRAST participants underwent repeated echocardiography (HDF: n=171; HD: n=171) and 189 underwent repeated PWV measurements (HDF: n=103; HD: n=86). A total of 159 patients underwent both echocardiography and PWV assessment.
The median baseline LVM was 227 g (25th-75th percentile, 183-279 g), median EF was 65% (25th-75th percentile, 55%-72%), and median PWV was 9.82 m/s (25th-75th percentile, 6.5-12.0 m/s).
Patients who underwent echocardiography had characteristics similar to those of the other CONTRAST patients who did not receive echocardiography (Supplemental Table 1). Patients who received PWV measurements were younger, had a lower body mass index, and had a higher diastolic BP than the other CONTRAST patients (Supplemental Table 1 ).
The participant flowcharts of the echocardiography cohort and the PWV cohort are shown in Supplemental Figures 1 and 2 , respectively. Dropout was high, mainly because of death and kidney transplantation. However, baseline patient characteristics did not differ between those who were followed for ,1 year and those followed for 1-3 years or .3 years (Supplemental Table 2 ). Effect of HDF on LVM LVM did not differ between HDF and HD during the trial, nor were there differences between treatment modalities in rate of change over time (Table 2) . When additional adjustments for predialysis systolic BP, hemoglobin, b 2 -microglobulin, and phosphate as time-varying covariates were made, results were similar (data not shown). Figure  1A shows the linear mean changes of LVM over time in HDF versus HD. Results were similar when LVM was indexed for body surface area or for height 2.7 (Supplemental Table 3 ).
No evidence was found for different effects of HDF compared with HD on LVM in different subgroups (Supplemental Table 4 ).
Effect of HDF on EF
EF remained stable in the HDF group (change, 20.3% per year; 95% confidence interval [95% CI], 22.3% to 1.8%; P=0.78) but decreased in the HD group (change, 23.4% per year; 95% CI, 25.9% to 20.9%; P=0.01) ( Table 2) . However, the rate of change did not differ significantly between dialysis modalities (P=0.17) and did not result in significantly different mean EFs. When additional adjustments described earlier were made, the results were similar (P for difference in rate of change between HDF and HD=0.15). Figure 1B shows the linear mean changes of EF over time in HDF versus HD.
No evidence was found for different effects of HDF compared with HD on EF in different subgroups (Supplemental Table 4 ).
Effect of HDF on PWV
PWV did not differ between HDF and HD during the trial, nor were there differences between treatment modalities in rate of change over time (Table 2 ). When additional adjustments described earlier were made, the results were similar (data not shown). Figure 1C shows the linear mean changes of PWV over time with HDF versus HD.
No evidence was found for different effects of HDF compared with HD on PWV in different subgroups (Supplemental Table 4 ).
Convection Volume
Rate of change in LVM, EF, and PWV during follow-up did not differ across the halves of mean convection volume in the HDF group compared with the HD group (Table 3) . When mean convection volume was divided into tertiles, or tested as a continuous variable, results were the same (data not shown).
Discussion
To our knowledge, this is the first randomized trial in a large ESRD population comparing the effects of online postdilution HDF versus HD on LVM, EF, and PWV. In this study, performed in a subpopulation of CONTRAST, we showed that HDF did not affect LVM, EF, or PWV compared with HD over 3-4 years. However, trends were observed for (1) an increase of LVM in the HD group, while LVM in the HDF group remained stable, and (2) a decrease of EF in the HD group, while EF in the HDF group remained stable; however, the differences between treatment groups were not significant.
Effect of HDF on LVM, EF, and PWV
Data regarding effect of HDF on alternative markers of cardiovascular risk are limited. In a randomized trial in 22 patients (9 receiving HD and 13 receiving online predilution HDF), Ohtake et al. showed that LVM index decreased significantly (by 12%) in the HDF group after 1 year but remained stable in the HD group after 1 year. In addition, PWV increased significantly by 11% in the HD group while remaining stable in the HDF group (22) . Our results did not confirm these findings, although with respect to LVM we observed a relation in the same direction, albeit not statistically significant. The differences between the Analyses were adjusted for baseline LVM/ PWV. P value comparing the slope to be different from zero. 95% CI, 95% confidence interval; EF, ejection fraction.
results of Ohtake et al. and our findings may be explained by the difference in the method of administering HDF (pre-versus postdilution) and differences in study population. Compared with the CONTRAST participants, patients in Ohtake and colleagues' study had a lower prevalence of cardiovascular disease and used less antihypertensive medication (22) . We could speculate that these patients had less cardiovascular damage at baseline and are prone to a more favorable course of surrogate marker change.
Francisco and colleagues' randomized trial in 24 patients (10 undergoing HD and 14 undergoing online postdilution HDF) showed a significant increase of EF in the HDF group after 3 months of follow-up (from 52%68% to 58%66%) versus no significant change in the HD group (23). Because we did not perform echocardiography at 3 months after randomization, our data cannot confirm the findings of Francisco et al. In addition, residual confounding may play a role in both of the above-described trials because the study sample was rather small.
Publication bias (i.e., studies with statistically significant results are more likely to be published) may explain the difference between our results and the positive results of two small trials comparing LVM, EF, and PWV in HDF and HD patients (24) .
In two observational studies comparing HDF and HD performed in 118 patients (HDF, n=58) and 333 patients (HDF, n=65), LVM index decreased in the HDF group and remained stable in the HD group over a follow-up period of 2 and 4 years, respectively (25, 26) . However, nonrandomized studies are prone to confounding by indication: It cannot be ruled out that patients with a more favorable prognosis were allocated to HDF. Furthermore, in both of these studies, changes in LVM index were not adjusted for potential confounders.
Our results, based on a large ESRD population, with extensive follow-up and with exploration of treatment effect in subgroups, indicate that during treatment with HD, the cardiac markers tend to worsen over 4 years (change in EF, 23.4%, P=0.01; change in LVM, 12.5 g, P=0.09), whereas no change occurred during treatment with HDF. The difference between HD and HDF, however, is not significant (P=0. 13 and P=0.17) . Earlier studies (in subgroups) of CONTRAST have shown that both phosphate and b 2 -microglobulin levels decrease in patients undergoing HDF and remain stable in HD recipients (16, 27, 28) . We cannot deduct from our data that better phosphate control and middle-molecule clearance lead to a more beneficial profile for LVM, EF, and PWV over a period of 3-4 years in our population.
Convection Volume
Post hoc analyses of three large randomized controlled trials-CONTRAST (16), the Turkish HDF Study (29) , and ESHOL (Estudio de Supervivencia de Hemodiafiltración On-Line) (30)-comparing HDF to HD in terms of mortality and cardiovascular events found a relation between high convection volumes and lower mortality risk. We did not find that high convection volumes were related to rate of change of LVM, EF, and PWV. Thus, we cannot determine whether the relation between high convection volume and low mortality is mediated by changes in cardiovascular anatomy or function.
Echocardiography Measurements
In our analyses, LVM was not indexed for body surface area or divided by height 2.7 , as was done in analogous studies (22, 25, 26) . A downside of ratios is that an observed relation may be due to changes in the nominator, the denominator, or both. Therefore, in the present analyses we chose to use sheer LVM. Because mixed models account for variability within patients, adjustment for body dimensions was not deemed necessary. For accuracy, when we performed the analyses with LVM indexed for height 2.7 or body surface area, results were similar (Supplemental Table 4 ).
Measurement errors could be considered a possible explanation for finding no associations. This is a multicenter trial, which may increase measurement variability, despite a uniform trained protocol. However, an experienced echocardiographer blinded for treatment assignment quantified the LVM measurements in a central core laboratory, thus reducing measurement variability.
Strength and Limitations
This study had several limitations. First, not all patients participating in CONTRAST underwent echocardiographic examinations, and not all of those patients had PWV assessments. Therefore, we probably do not have the power to demonstrate significant differences of LVM, EF, and PWV in patients undergoing HDF versus those undergoing HD, in particular for PWV because the sample size was smaller and the confidence intervals for the rate of change were wide in this group. Lack of power is even more probable in the analyses that demonstrate differences across subgroups of conventional risk factors. Second, some patients dropped out or missed examinations during the follow-up period. Although mixed-effect models can estimate rate of change well with some missing data, the precision of the estimates decreases.
The strengths of this study are the randomized design, the concise data collection over a long period of follow-up, and the double independent analysis of the echocardiography recordings. Furthermore, the study was performed in a large dialysis population involving patients from 6 university and 12 community hospitals and is among the largest reported thus far on this topic.
In conclusion, we did not find that treatment with HDF has a significant effect on changes in LVM, EF, and PWV compared with HD. Furthermore, no statistically significant differences in changes of LVM, EF, and PWV were found across subgroups of conventional risk factors.
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